Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today ...

CE-IVD certification puts Ella in focus for Bio-Techne investors Bio-Techne (TECH) just secured CE-IVD marking for its Ella benchtop immunoassay platform in the European Union, opening the door for ...

Bio-Techne's Ella platform achieves CE-IVD marking expanding access to rapid, cartridge-based immunoassays for European clinical labs: Minneapolis Tuesday, February 17, 2026, 14:0 ...

In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of ...

The global growth factors market is growing steadily, expected to be valued at approximately US$2.5 billion in 2026 and ...

The global growth factors market is growing steadily, expected to be valued at approximately US$2.5 billion in 2026 and projected to reach US$3.7 billion ...

Bring IT, a global cloud ERP consulting, implementation, and integration leader, announced today that it has been named the 2026 Partner of the Year by Celigo, a leading enterprise integration ...

ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, and its wholly owned subsidiary Cordex Biologics (Cordex), announced that Zemcelpro® (dorocubicel), ...

The rising prevalence of various infectious diseases, such as malaria, leishmaniasis, and HIV-AIDS, globally is directly propelling the demand for ELISpot and fluoroSport assays. Cancer also covers a ...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my ...

NEW YORK — Bio-Techne said on Monday that its Ella benchtop immunoassay platform has received CE-IVD marking, permitting its sale in the EU.

Techne's Ella ELISA platform to run its ovarian cancer test, advancing toward FDA 510(k) filing and supply deal.